Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10038918 | 0.78 | KMT2A (0.49) | MAPTKMT2ANOTUMALDH1A1CYP1A2 | |
| SCHEMBL3614888 | 0.77 | — | — | |
| SCHEMBL3080090 | 0.74 | — | — | |
| SCHEMBL18672305 | 0.72 | — | — | |
| SCHEMBL11260067 | 0.72 | — | — | |
| SCHEMBL8157077 | 0.72 | NAAA (0.56) | KMT2AL3MBTL1 | |
| SCHEMBL7752266 | 0.68 | POLB (0.41) | INMTMAPTKMT2ANOTUMALDH1A1 | |
| SCHEMBL16375967 | 0.68 | NAAA (0.56) | MAPTL3MBTL1TP53 | |
| SCHEMBL16375970 | 0.67 | DPP4 (0.38) | NOTUMDPP4PREPFAPDPP8 | |
| SCHEMBL16375966 | 0.66 | SLC6A3 (0.35) | INMTMAPTKMT2ANOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | claimed |
| EP-1032424-B9 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1454902-A1 | N- (substituted five-membered di-or triaza diunsaturated ring)carbonyl guanidine derivateives for the treatment of ischemia | Pfizer Products Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | claimed |
| EP-1032424-B1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| EP-1032424-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | Pfizer Products Inc. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
| WO-1999026659-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-1032424-B9 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1032424-B1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PROD INC (US) | 2001-09-12 | — | — | EP | disclosed |
| CN-1279617-A | Combination of an aldose reductase inhibitor and a glycogen phosphorglase inhibitor | PFIZER PROD INC (US) | 2001-01-10 | — | — | CN | disclosed |
| EP-1032424-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | Pfizer Products Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999026659-A1 | COMBINATION OF AN ALDOSE REDUCTASE INHIBITOR AND A GLYCOGEN PHOSPHORYLASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | INMT 2321/4885MAPT 4820/4885KMT2A 4726/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | INMT 1736/4885MAPT 4649/4885KMT2A 4758/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | INMT 1244/4885MAPT 4418/4885KMT2A 3222/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | INMT 1593/4885MAPT 4477/4885KMT2A 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.